What is Acticor Biotech?
Acticor Biotech is a clinical-stage biopharmaceutical company dedicated to pioneering novel therapies for thrombotic diseases, with a particular emphasis on acute ischemic stroke. The company's lead candidate, Glenzocimab, is a first-in-class therapeutic agent engineered for emergency cardiovascular interventions and acute thrombotic conditions. Originating as a spin-off from the French National Institute of Health and Medical Research (INSERM), Acticor Biotech is committed to addressing critical unmet medical needs in stroke management and related vascular emergencies.
How much funding has Acticor Biotech raised?
Acticor Biotech has raised a total of $12.8M across 4 funding rounds:
Private Equity
$1.5M
Private Equity
$1.6M
Series A
$2M
Series B
$7.6M
Private Equity (2016): $1.5M, investors not publicly disclosed
Private Equity (2017): $1.6M led by Karista
Series A (2018): $2.1M supported by Anaxago, Karista, and Primer Capital
Series B (2019): $7.6M featuring Anaxago, Newton BioCapital, Karista, and Go Capital
Key Investors in Acticor Biotech
Karista
Karista is an independent venture capital firm with two decades of experience backing European companies in Digital, Technology, and Healthcare. They focus on providing support to founders and entrepreneurs from the early stages of development.
Go Capital
GEOC, a China-Israel fund, invests in Israeli high-tech companies across Life Sciences, Digital/3D printing, Cyber Security, and AI. They offer strategic investment with a focus on facilitating market penetration in China and identifying strategic partners.
Anaxago
Anaxago is an investment platform that supports innovative companies. Their participation in Acticor Biotech's funding round highlights their interest in the biopharmaceutical sector.
What's next for Acticor Biotech?
The substantial enterprise-level funding signifies Acticor Biotech's advanced stage in its development lifecycle, likely positioning it for pivotal clinical trials and potential commercialization efforts. This capital infusion is expected to accelerate the advancement of Glenzocimab through regulatory pathways and expand the company's research and development capabilities. The strategic backing from investors suggests confidence in Acticor Biotech's therapeutic approach and its potential to capture a significant share of the market for stroke and thrombotic disease treatments.
See full Acticor Biotech company page
